Abstract | Myocardial infarction triggers an intense inflammatory response that is essential for cardiac repair, but which is also implicated in the pathogenesis of postinfarction remodelling and heart failure. Signals in the infarcted myocardium activate toll-like receptor signalling, while complement activation and generation of reactive oxygen species induce cytokine and chemokine upregulation. Leukocytes recruited to the infarcted area, remove dead cells and matrix debris by phagocytosis, while preparing the area for scar formation. Timely repression of the inflammatory response is critical for effective healing, and is followed by activation of myofibroblasts that secrete matrix proteins in the infarcted area. Members of the transforming growth factor β family are critically involved in suppression of inflammation and activation of a profibrotic programme. Translation of these concepts to the clinic requires an understanding of the pathophysiological complexity and heterogeneity of postinfarction remodelling in patients with myocardial infarction. Individuals with an overactive and prolonged postinfarction inflammatory response might exhibit left ventricular dilatation and systolic dysfunction and might benefit from targeted anti-IL-1 or anti-chemokine therapies, whereas patients with an exaggerated fibrogenic reaction can develop heart failure with preserved ejection fraction and might require inhibition of the Smad3 (mothers against decapentaplegic homolog 3) cascade. Biomarker-based approaches are needed to identify patients with distinct pathophysiologic responses and to rationally implement inflammation-modulating strategies.
Introduction
More than 70 years ago, cardiac pathologists noted that myocardial infarction triggers an intense inflammatory reaction characterized by infiltration of leukocytes into the infarcted heart. 1 In the following decades, recognition of the injurious properties of leukocytes and their close association with cardiomyocytes in the viable border zone of an infarct suggested that subpopulations of blood-derived cells can adhere to viable cardiomyocytes and might exert cytotoxic effects extending ischaemic injury ( Figure 1 ). 2 In the 1980s and 1990s, experimental studies demonstrated that targeting leukocyte-mediated inflammation in reperfused myocardial infarction markedly reduced the size of the infarct, and thereby prevented an extension of ischaemic cardiomyocyte injury. [3] [4] [5] [6] Approaches targeting molecules involved in leukocyte activation, adhesion, and extravasation (such as integrins, selectins, and components of the complement cascade) were successful in animal studies in attenuating ischaemic injury, leading to considerable enthusiasm for their potential use in humans. [3] [4] [5] Unfortunately, despite promising data from animal studies, translation of leukocyte-focused treatment into therapy for human populations with myocardial infarction was un successful, and several anti-inflammatory approaches failed to reduce infarct size in clinical investigations. 6 The disappointment from these early negative clinical results had lasting consequences in the field. Considering the critical role of the inflammatory cascade in response to cardiac injury, and the involvement of inflammatory mediators in repair and remodelling of the infarcted heart, the reduced interest in this therapeutic direction was unfortunate. The pathogenesis of heart failure after myocardial infarction is intricately linked with the development of postinfarction ventricular remodelling. Structural, functional, and geometric alterations that involve both the infarcted and noninfarcted myo cardial segments and lead to chamber dilatation, increase spher icity of the ventricle and cardiac dysfunction. 7 Cardiac remodelling is associated with the progression of heart failure, increased incidence of arrhythmias, and poor prognosis in patients surviving a myocardial infarction. 8 The extent of postinfarction remodelling is dependent on the infarct size and quality of cardiac repair. 9 Experimental studies have called into question the notion that inflammatory signals can extend ischaemic injury, 10, 11 but inflammatory pathways are undoubtedly critically involved in dilative and fibrotic remodelling of the infarcted heart and, therefore, drive key events in the pathogenesis of postinfarction heart failure.
In this Review, I discuss the role of inflammatory signals in regulating repair and remodelling of the infarcted heart, and the attempts to identify therapeutic targets. From advances in the understanding of pathophysiology of cardiac remodelling, I will attempt to provide a guide for development of anti-inflammatory treatments for patients who survive a myocardial infarction.
Postinfarction inflammatory response
The adult mammalian heart has little regenerative capacity, therefore, healing of the infarcted myo cardium is dependent on an orchestrated sequence of cellular events that lead to the formation of a collagen-based scar. Repair of the infarcted myocardium can be described in three overlapping phases: the inflam matory phase, the proliferative phase, and the maturation phase. 12 Acute sudden death of cardiomyocytes in the infarcted heart rapidly activates innate immune pathways that trigger an intense, but transient, inflammatory reaction. This response clears the infarcted area of dead cells and extracellular matrix debris, and is then actively repressed to prepare the infarct for the proliferative phase of healing. During the proliferative phase, mononuclear cell and macrophage subpopulations secrete growth factors that recruit and activate mesenchymal reparative cells-predominantly myofibroblasts and vascular Key points ■ In the infarcted myocardium, cardiomyocyte death and degradation of the cardiac extracellular matrix releases signals that activate innate immune pathways and trigger an intense inflammatory reaction ■ The role of postinfarction inflammation in extending ischaemic cardiomyocyte injury is controversial; however, inflammatory mediators are implicated in dilative remodelling and in the pathogenesis of postinfarction heart failure ■ Early stimulation of inflammatory signalling is important for clearance of dead cells from the infarcted area and for tissue repair ■ Timely repression of proinflammatory mediators protects the heart from excessive inflammatory injury ■ Patients who survive a large myocardial infarction exhibit pathophysiological heterogeneity, as subpopulations with progressive dilative remodelling or predominant diastolic dysfunction are identified ■ Biomarker-based approaches are needed to identify patients with overactive proinflammatory signalling or excessive fibrosis who might benefit from targeted therapies cells. The myofibroblasts secrete large amounts of extracellular matrix proteins, thereby preserving the structural integrity of the left ventricle. Apoptosis of the majority of reparative cells marks the end of the proliferative phase, as the infarct matures and a scar comprised of cr oss-linked collagen is formed.
12

Necrosis and innate immune signals
Tissue injury generates endogenous signals that activate the innate immune system; these molecules belong to a large family of mediators that warn the body of injury and are known as danger-associated molecular patterns (DAMPs). 13, 14 The term 'alarmins' describes a group of structurally diverse endogenous signals that, when released after tissue necrosis, promote activation of innate immune cells by binding to pattern recognition receptors. 15 The best characterized alarmin-high mobility group protein B1 (HMGB1)-is a key initiator of inflammatory injury following myocardial ischaemia through actions that might involve toll-like receptors (TLRs), a family of transmembrane receptors that activate downstream proinflammatory cascades, and the receptor for advanced glycation end products (RAGE). 16, 17 Considering the fundamental role of alarmin-mediated signalling in inflammation and repair, the fact that both detrimental 16, 17 and beneficial 18 effects of HMGB1 have been reported in the infarcted m yocardium is not surprising.
Other intracellular constituents released by necrotic cells, such as heat shock proteins and ATP, might also activate an immune response in the infarcted heart. 13, [19] [20] [21] The damaged extracellular matrix might also transduce key signals for activation of innate immune cells in the infarcted heart. Low molecular weight hyaluronan and fibronectin fragments can activate TLRs and function as important initiators of proinflammatory signalling. Innate immune cells identify danger signals via engagement of TLRs. Of the 13 members of the mammalian TLR family, genetic loss-of-function studies indicate that TLR2 and TLR4, both localized on the cell surface, are important mediators of the postinfarction inflammatory reaction. [24] [25] [26] Activation of the complement system is also involved in transducing the immune response in the infarcted heart, and complement inhibition attenuates leukocyte recruitment after myocardial infarction. 27 Ischaemia-mediated generation of reactive oxygen species (ROS) is also important for the activation of inflam matory signals in the infarcted myocardium. ROS promote leukocyte infiltration into the healing infarct by activating all steps of inflammatory cell recruitment. [28] [29] [30] ROS contribute to generation of chemotactic gradients in three ways: by inducing chemokine and cytokine expression, 28 by promoting leukocyte integrin activation, 29 and by inducing adhesion molecule synthesis. 30 
Chemokines and cytokines
Activation of alarmin-mediated signalling induces a molecular programme that leads to the recruitment of inflammatory cells in the healing infarct. Induction of proinflammatory chemokines in the infarcted heart generates chemotactic gradients that recruit leukocyte subpopulations via interactions with the corresponding chemokine receptors. Upregulation of proinflammatory cytokines (such as tumor necrosis factor [TNF], IL-1β and members of the IL-6 family) induce endothelial cell adhesion molecule synthesis and activate leukocyte integrins, mediating strong adhesive interactions that ultimately lead to extravasation of inflammatory cells into the infarct. 9 The role of chemokines Expression of both major chemokine subfamilies (the CC and CXC chemokines) is increased in the infarcted heart and mediates recruitment of inflammatory leukocytes. 31 CXC chemokines containing the tripeptide sequence Glu-Leu-Arg (known as the ELR motif, and also found in IL-8 in placental or eutherian mammals and the cor responding CXCR2 ligands in mice), 32 are rapidly induced in the infarcted myocardium and mediate recruitment of neutrophils. 33 Trafficking of mononuclear cell subsets involves CC chemokine signalling; distinct interactions between chemokines and their receptors might be respon sible for recruitment of different sub populations of mononuclear cells. CC motif chemokine 2 (also known as monocyte chemoattractant protein 1 [MCP-1]) is rapidly upregulated in the infarcted myocardium and mediates recruitment of proinflammatory phagocytotic monocytes that clear the area of dead cells and matrix debris. 34 Chemokines might also recruit inhibitory and reparative mononuclear cell subsets into the infarct; however, the specific chemokine-chemokine-receptor pairs mediating these cellular events remain poorly understood. Interactions involving the CC chemokine receptor type 5 might be involved in recruitment of mononuclear cell subpopulations with anti-inflammatory properties, such as inhibitory monocyte subsets and regulatory T cells. 35 Systematic characterization of monocyte subsets infiltrating the infarcted myocardium and understanding of the mechanisms mediating their recruitment has important therapeutic implications.
The role of proinflammatory cytokines Expression of the proinflammatory cytokines TNF, IL-1β, and IL-6 is markedly and consistently increased in experimental models of myocardial infarction. 36, 37 However, the pleiotropic properties of these cytokines and their multi functional effects on all cell types involved in cardiac injury and repair have hampered our understanding of their functional roles in the infarcted and remodelling heart. TNF is released following myocardial infarction, 38 and can promote inflammatory injury inducing chemokine and adhesion molecule synthesis in the infarcted myocardium. 39 As a highly pleiotropic mediator, TNF can also protect cardiomyocytes from apop tosis. 40 Divergent effects transduced through TNF receptors 1 and 2 might regulate remodelling of the infarcted heart. 41 The failure of anti-TNF strategies in patients with chronic heart failure 42 might reflect the pleio tropic actions of the cytokine, and has discouraged the design of approaches targeting the pathway in myocardial infarction. IL-1β is also markedly induced in the infarct and mediates inflammatory leukocyte recruitment and activation, 43, 44 while delaying myofibroblast activation. 44 No protective effects of IL-1 on cardiomyocytes have been reported, and because IL-1 neutralization can attenuate cardiomyocyte apoptosis in vitro and in vivo, 45 inhibition of IL-1 following myocardial i nfarction might have no major detrimental consequences. 46 IL-6 is also upregulated in the infarcted myocardium, and might modulate the inflammatory and reparative response signalling through IL-6 receptor subunit beta and activating the JAK/STAT (janus tyrosine kinase/ sig nal transducer and activator of transcription) cascade. 47 Blocking IL-6 function has been effective in the treatment of rheumatic disorders. 48 However, the pleiotropic effects of IL-6 in the healing infarct and the induction of other IL-6 receptor family members that might compensate for the loss of this cytokine, raise concerns about its potential role as a therapeutic target in patients with myocardial infarction. Experimental studies in IL-6-knockout mice demonstrated that the loss of IL-6 does not affect cardiac function and remodelling in a model of nonreperfused infarction. 49 Other IL-6 family cytokines might compensate for the loss of IL-6 by activating JAK/STAT signalling and maintaining STAT3 phosphorylation. Conversely, treatment with an anti-IL-6 receptor antibody attenuated adverse remodelling in a mouse model of nonreperfused infarction. 50 Timely down regulation of the IL-6 response might be important for infarct healing. In a mouse model of myocardial infarction, impaired suppression of IL-6 receptor/STAT3 signalling was associated with prolonged and enhanced inflammation increasing the incidence of cardiac rupture. 51 
Effectors of postinfarct inflammation
The inflammatory response in the infarcted myocardium involves cells that are normally found in the REVIEWS heart and newly recruited cells ( Figure 2) ; however, the relative contribution of the different cell types remains unclear. In the absence of injury, the adult mammalian myocardium contains relatively small populations of macrophages, mast cells, 52 and dendritic cells. 53 Cardiac resident mast cells contain preformed proinflammatory cytokines, and can be rapidly activated following myocardial ischaemia releasing their granular content and triggering the inflammatory cascade. 38 ROS generation, adenosine, and complement factor C5a might stimulate mast cell degranulation. [54] [55] [56] The function of TLR ligands in this context is less convincingly established. In the early hours after myocardial infarction, leukocytes (neutrophils and mononuclear cells) rapidly infiltrate the infarct. Circulating neutrophils are recruited through activation of both chemokine-dependent 28 and chemokineindependent pathways. 57, 58 Monocyte subpopulations infiltrate the myocardium s equentially-first by proinflammatory monocytes that are rapidly mobilized from the bone marrow and the splenic r eservoir. 59 Recruitment of inflammatory monocytes into the infarcted heart is the result of marked upregulation of the MCP-1. 34 Experiments in a mouse model of non reperfused infarction suggested that B lymphocytes might mediate chemokine-driven mobilization of proinflammatory monocytes in the infarct. 60 Reparative monocytes follow the proinflammatory cells, but the signals involved their recruitment remain poorly understood. Macrophage subsets with proinflammatory properties also infiltrate the infarct and might sustain a proinflammatory environment in the infarcted myocardium. 61 The concept suggesting recruitment of two polarized populations of monocytes or macrophages in the infarct represents an oversimplification, because several subpopulations of cells with distinct functional properties (and perhaps also with varying potential for differentiation and activation) are probably recruited in the infarcted myocardium.
As the most abundant noncardiomyocyte population in the mammalian heart, fibroblasts might also contribute to the initiation of the inflammatory reaction in the infarcted myocardium. Activation of the inflammasome cascade (the molecular platform that triggers activation of inflammatory caspases and processes pro-IL-1β) has been demonstrated in infarct fibroblasts, 62 which might reflect an important role for these versatile cells in proinflammatory signalling. During the early stages of the postinfarction response, fibroblasts acquire a proinflammatory and matrix-degrading phenotype; local release of 57 Capture (1) of circulating leukocytes by activated endothelial cells is followed by rolling (2), mediated through interactions involving the selectins. Rolling leukocytes are activated (3) by chemokines bound to PG on the endothelial surface. Activated leukocytes express integrins and adhere to endothelial cells (4) . Strengthening of the adhesive interaction (5) between leukocytes and endothelial cells is followed by transmigration of the cells into the infarcted area (6) . Abbreviations: C5a, complement factor 5a; DAMP, danger-associated molecular pattern; PG, proteoglycan; ROS, reactive oxygen species; TLR, Toll-like receptor.
IL-1 might inhibit their conversion into matrix-synthetic myofibroblasts 44 until the infarct microenvironment is cleared from dead cells and matrix debris and can support deposition of a new collagen-based matrix.
The heart is abundant with blood vessels, endothelial cells might, therefore, be important in the synthesis and release of proinflammatory cytokines and chemokines. 31 Descriptive studies in canine models have identifie d venular endothelial cells as an important source of chemokines in the infarcted myocardium. 63, 64 ROS generation and activation of TLR signalling by alarmins released by dying cells and matrix debris might mediate inflammatory activation of the infarct endothelium. Platelets also accumulate within the infarcted myo cardium and might be important for the inflammatory reaction, both through direct release of cytokines and chemokines and by modulating phenotype of other cell types. 65 Dying cardiomyocytes are crucial for triggering inflammatory pathway activation through release of DAMPs; however, the potential role of viable border zone cardiomyocytes as a source of inflammatory mediators remains unclear. In a canine model of reperfused myocardial infarction, border zone cardiomyocytes have been identified as a source of IL-6. 66 However, noncardiomyocytes (including leukocytes, vascular cells, and fibroblasts) can produce large amounts of cytokines and chemokines; 38, 64, 67 therefore, the relative importance of c ardiomyocyte-derived inflammatory mediators is unknown.
Effective repair and inflammation
Repair of injured tissues is dependent on timely suppression and containment of inflammation. This process is accompanied by activation of mesenchymal cells that restore tissue integrity. Extensive experimental work suggests that repression of proinflammatory signalling is not a passive process, but requires induction of inhibitory molecules and activation of suppressive pathways. 68 In injured tissues, overactive, prolonged, or spatially expanded inflammatory reactions lead to accentuated damage and dysfunction. Myocardial function is intricately linked with preservation of structural integrity, impaired suppression or defective containment of inflammation in the injured heart can, therefore, have catastrophic consequences. Prolonging inflammatory signalling in the infarcted heart might have many consequences, including loss of cardiomyocytes, suppression of systolic function, enhanced matrix-degrading processes leading to chamber dilation, increased tissue breakdown causing loss of ventricular wall integrity and cardiac rupture, and extended fibrotic changes beyond the initial infarct. Extensive experimental evidence, derived from mouse models with impaired repression or resolution of the inflammatory response, suggests that overactive inflammatory signalling leads to increased left ventricular dilatation following myocardial infarction. 11, 35, 69, 70 Whether such defects lead to dilative remodelling in humans has not been established. However, evidence from clinical studies suggests that patients with persistent elevation of serum inflammatory biomarkers (such as MCP-1) 1 month after an acute coronary syndrome have increased mortality in the absence of an increase in new coronary events. 71 Adverse prognosis in these patients might reflect increased remodelling and accentuated injury in individuals with defective a ctivation of anti-inflammatory pathways. 72 
Anti-inflammatory signalling
All cell types involved in cardiac repair likely participate in repression and resolution of the postinfarction inflammatory reaction; however, the key cellular effectors that drive inhibition of inflammation remain unknown. Through their unique cytokine expression profile, and their potential for regulated recruitment and activation in response to local stimuli, inhibitory subsets of monocytes and lymphocytes and anti-inflammatory macro phages are ideally suited to suppress inflammation in the infarcted heart. Experimental studies have demonstrated dynamic changes in macrophage phenotype in the infarcted heart, which suggests a transition from early infiltration with proinflammatory M1 cells to the late predominance of reparative M2 macrophages. 73 The signals leading to these phenotypic changes of infarct macrophages remain poorly understood, and two questions remain: are macrophage subsets derived from distinct monocyte subpopulations, and do dynamic changes in the infarct microenvironment mediate acquisition of an inhibitory profile?
Evidence suggests that the phagocytotic activity of macrophages can be important for modulating their phenotype and in repression of the inflammatory reaction. Efficient clearance of apoptotic cells by phagocytes (known as efferocytosis) activates proresolving signals that might aid the transition from inflammation to repair. The induction of tyrosine-protein kinase Mer in macrophages seems to be important for cardiomyocyte efferocytosis and subsequent suppression of the post-infarction inflammatory reaction. 74 Inhibitory lympho cyte subpopulations, such as regulatory T cells, can participate in suppression of the postinfarction inflammatory response. 35 Moreover, fibroblasts and vascular cells are abundant in the healing infarct and might also contribute to suppression of inflammatory signalling. Acquisition of a pericyte coat by angiogenic vessels in the infarcted heart might suppress inflammatory activity s tabilizing the microvasculature and preventing prolonged recruitment of leukocytes. 75 
Molecular stop signals
Negative regulation of proinflammatory signalling pathways is essential to maintain tissue homeostasis and activate the reparative response after the clearance of dead cells. Both intracellular molecules and soluble mediators have been implicated in the inhibition of the inflam matory reaction following myocardial infarction. In our own work, we have identified IL-1 receptorassociated kinase 3 (IRAK-3; also known as IRAK-M), a member of the IRAK family. IRAK-3 does not activate inflammation, but functions as an inhibitor of innate immune signalling 76 and as an essential intracellular molecule for repression of macrophage-driven inflammation and fibroblast-mediate d matrix degradation following myocardial infarction.
11 IRAK-3 is expressed in fibroblasts and a subset of infarct macrophages, and promotes an anti-inflammatory phenotype that inhibits cytokine expression. In addition to induction of intracellular signals that make cells less responsive to proinflammatory activation, expression of decoy cytokine and chemokine receptors, and release of soluble inhibitory mediators might be important additional mechanisms involved in suppression of the inflammatory reaction. Members of the transforming growth factor β (TGF-β) family, [77] [78] [79] IL-10, 80 and p roinflammatory-resolving lipid mediators 81 have been identified as secreted mediators that might act as i nhibitors of the postinfarction i nflammatory reaction.
From inflammation to fibrosis
Repression of inflammation in the infarcted heart is associated with activation of mesenchymal cells that deposit extracellular matrix proteins, thereby preserving the structural integrity of the infarcted heart. The adult mam malian heart contains an abundant population of interstitial and perivascular fibroblasts; 82,83 these cells can trans differentiate into myofibroblasts, cells that express contractile proteins (such as α-smooth muscle actin) and are key for repair of the infarcted myocardium by secreting matrix proteins. [84] [85] [86] In addition to the resident cardiac fibroblasts, bone marrow-derived fibroblast progenitors, endothelial cells undergoing transdifferentiation into m esenchymal cells, smooth muscle cells, and pericytes might contribute to the infarct myofibroblast population. [87] [88] [89] [90] [91] Conversion of fibroblasts into myofibroblasts requires the co-operation of several microenvironmental factors: activation of TGF-β, a key mediator in induction of contractile proteins in mesenchymal cells; expression and deposition of specialized matrix proteins, such as ED-A fibronectin and matricellular proteins; 92 increased mechanical stress triggered by the disruption of the normal matrix network; and removal of proinflammatory mediators (such as IL-1β) that inhibit myofibroblast conversion.
Transforming growth factor β Activation of TGF-β signalling cascades is a key molecular link between the inflammatory and reparative response (Figure 3) . Latent TGF-β is stored in the myocardium and can be rapidly activated following injury. Generation of ROS, induction of matricellular proteins (such as thrombo spondin-1), and activation of proteases contribute to activation of preformed TGF-β in the infarcted area. 92, 93 Moreover, platelets, leukocytes and fibroblasts infiltrating the infarcted heart synthesize and release de novo TGF-β, further increasing its levels. 67 TGF-β bio activity is increased during the early hours after infarction; 94 however, the abundance of proinflammatory medi ators at this stage might reduce cellular responsiveness to TGF-β, delaying myofibroblast transdifferentiation and matrix deposition until the infarct is cleared from dead cells and matrix debris. 44 As proinflammatory signalling is repressed, TGF-β signalling promotes myofibroblast transdifferentiation and activates a matrix-preserving molecular programme, inducing expression of collagens and fibronectin, while upregulating synthesis of protease inhibitors (such as metalloproteinase inhibitor 1). 95 TGF-β signals through activation of intracellular effectors, the Smads, and through Smad-independent pathways (such as, mitogen-activated protein kinases). Experimental evidence suggests that the profibrotic, matrix-preserving actions of TGF-β in fibroblasts are predominantly mediated through activation of Smad3 signalling; 95, 96 the potential involvement of smad-independent cascades remains poorly understood. The TGF-β signalling cascade interacts with several other important pathways that regulate the fibrogenic response in the remodelling myocardium. Neurohumoral mediators, such as angiotensin II 97 and aldosterone 98 are important for fibroblast activation; their effects might be mediated in part through activation of TGF-β signalling. 99 Moreover, the Notch pathway-a signalling cascade critically involved in cardiac fibrotic responses-negatively regulates the TGF-β/Smad response. 100, 101 In addition to the critical effects of angiotensin II and of the TGF-β/Smad cascade, other fibrogenic growth factors (such as platelet-derived growth factors) might modulate fibroblast phenotype regulating their p roliferation, synthetic profile, and migratory activity.
Targeting the infarcted heart
Lessons from the past Unfortunately, translation of early evidence that antiinflammatory strategies might reduce infarct size into a clinical context has been disappointing. Although anti-CD11/CD18 integrin approaches were very effective at reducing infarct size in experimental models, [102] [103] [104] three small clinical trials targeting β2 integrins in patients with myocardial infarction did not demonstrate beneficial effects. [105] [106] [107] A large clinical trial targeting the complement system, a pathway critical in activation of the postinfarction inflammatory reaction, also showed no benefit in patients undergoing percutaneous inter ventions for acute myocardial infarction. 108 These failures had a lasting influence and reduced enthusiasm for the potential clinical usefulness of anti-inflammatory approaches in patients with myocardial infarction. Moreover, such failures question the usefulness of animal models in predicting the success of therapeutic approaches. 109 What is the reason for the apparent disconnect between findings in animals and clinical investigations? Why is translating promising approaches to the clinical context so difficult, despite abundant evidence in experimental models?
The academic community and public are often overly optimistic about new and promising therapeutic strategies. Studies with impressive positive results generate great enthusiasm and are more likely to be published. Laboratories reporting these observations are more likely to attract funding and have a better chance of completing their work. During the early stages after the introduction of a new concept, therefore, the literature often reflects a publication bias that favours positive findings and results in overly optimistic appraisal of the therapeutic potential of a strategy. Only after a concept is established in the scientific community does the publication of negative studies becomes attractive; by which time the published work might better reflect the collective experience of the scientific community. In the field of cardiac injury and repair, the abundant early reports suggesting that infarct size could be reduced using anti-inflammatory strategies were later challenged by studies in genetically targeted animals showing that postinfarction inflammation does not extend ischaemic cardiomyocyte injury. 10, 34, 43 Animal models are great tools for dissection of pathophysiological concepts. However, these results cannot directly predict effectiveness in a clinical context, owing to limitations of the animal model itself and the complex pathophysiology of human diseases. Animal models of myocardial infarction cannot, therefore, fully recapitulate the clinical outcome observed in humans. In clinical trials, mortality is the most important end point; by contrast, mortality data in animal investigations are often difficult to interpret and do not always provide evidence that can be easily translated to humans. Cardiac rupture is the most-common cause of death in mouse models of nonreperfused myocardial infarction, 49, 69 but is uncommon in humans and its incidence has declined over the past 30 years, owing to the introduction of reperfusion strategies and advances in medical care. 110 Conversely, ventricular arrhythmias are a common causes of death in patients with acute myocardial infarction, but in mouse models the incidence of fatal arrhythmias is low and the mechanisms of arrhythmogenesis might differ owing to the small size of the mouse heart and its rapid beating rate. Moreover, animal models of surgical coronary occlusion do not provide information on the incidence of recurrent coronary events, and the severity of postinfarction heart failure as a clinical syndrome cannot be reliably assessed in mice. Conclusions about outcomes in animal models of myocardial infarction are often based on extrapolation from data reflecting specific functional end points. Although these conclusions might provide important and accurate pathophysiological insights, direct relevance to clinical outcome is limited.
Perhaps the most-important reason for the challenges in translating experimental findings into clinically relevant information for myocardial infarction, specifically, is the pathophysiological complexity and heterogeneity of the condition in humans. Optimally executed investigations in animal models are designed to eliminate variability, test a hypothesis, and provide insights into a molecular pathway or cellular process. In a typical lossof-function study to examine a specific mediator, the goal is to compare responses of age-matched and sexmatched animals with identical genetic backgrounds that only differ in the presence or absence of the mediator of interest. This strategy is optimal for understanding the pathophysiology of disease, but unfortunately limits our ability to make translational predictions. Patients with myocardial infarction differ in a wide range of factors that affect outcome. Genetic profile, age, sex, the presence of comorbid conditions (such as hypertension, hyperlipidaemia and diabetes mellitus), treatment with pharmacological agents, and the pattern of the disease, are some of the important clinical variables that can profoundly affect the response to myocardial infarction. Considering the complexity of the human pathophysiology, attempts to introduce these variables and generate an animal model of high predictive value are imprac tical. An illustration of the profound effects of one of these factors on the postinfarction inflammatory and reparative response is provided by our experience in senescent animals. In a model of reperfused myocardial infarction, aging was associated with a marked suppression (and modest prolongation) of the inflammatory reaction following reperfused myocardial infarction. 111 On the basis of these observations, one reason that explains the lack of effectiveness of targeted anti-inflammatory strategies in humans might be the advanced age of many patients with myocardial infarction. Young animals have been used in all studies showing beneficial effects of anti-inflammatory strategies after myocardial infarction. The failure of these therapies in humans might, therefore, reflect a less robust inflammatory reaction in older individuals. The dysregulated immune responses associated with senescence complicate efforts to design therapeutic strategies targeting the postinfarction inflammatory reaction.
The future: modulating inflammation Successful clinical translation requires both pathophysiological insights and an understanding of the clinical context. Implementation of this simple principle is of paramount importance in myocardial infarction. Over the past 30 years, experimental studies have revealed important mechanisms in the reparative and remodelling responses that occur after myocardial infarction. Experiments using animal models have highlighted the complexity of inflammatory pathways-cytokines and growth factors are highly pleiotropic mediators that exert multiple effects on all cell types involved in cardiac injury and repair. Understanding the temporal and spatial regulation of inflammatory signals is critical to the design effective therapies. For example, early activation of cytokine and chemokine pathways might be important in clearing the infarct of dead cells and debris, and for stimulation of downstream reparative cascades.
However, prolonged or excessive induction of proinflammatory signalling is associated with accentuated injury and increased adverse remodelling. Spatial containment of inflammatory cascades is equally important-effective repair is dependent on signals that prevent extension of the inflammatory response into the viable myocardium, therefore, limiting fibrosis to the infarcted region.
Proinflammatory mediators, such as TNF, often exert both detrimental and protective responses on the same cell type mediated through distinct receptorsdissection of the pathways involved in these effects might lead to more specific and effective therapeutic strategies. The growing interest in cardiac regeneration through cell therapy [112] [113] [114] has added a new perspective to the potential role of inflammatory signals in cardiac repair, stressing the role of selected chemokines (such as stromal cell-derived factor 1 [also known as CXC motif chemokine 12]) 115 cytokines, and growth factors, 116, 117 in regulating trafficking, activation, differentiation, and survival of progenitor cells. The effect of inflam matory signalling in extending ischaemic cardio myocyte injury remains controversial; however, the involvement of inflammatory and fibrogenic signals in cardiac remodelling and in the development of postinfarction heart failure is already well-established. In the infarcted myocardium, left ventricular geometry and function are dependent on the balance between matrixdegradin g and matrix-preserving signals. Overactive matrix-degrading processes caused by local activation of matrix metalloproteases by proinflammatory mediators, such as IL-1β and MCP-1, are generally associated with decreased tensile strength, leading to left ventricular dilatation and systolic dysfunction. Degradation of the inter stitial matrix is also associated with cardiomyocyte slippage and might lead to cardiomyocyte death owing to deprivation of key prosurvival signals transduced by the matrix. 23 Conversely, overactive matrix-preserving responses, possibly associated with accentuated TGF-β signalling cascades, promote fibrosis and might cause diastolic dysfunction. Patients with myocardial infarction exhibit very different remodelling responses, which are at least in part independent of the size of the infarct. The molecular determinants of geometric remodelling in patients with myocardial infarction remain unknown; however, one could speculate that exaggerated left ventricular dilatation might reflect overactive proinflammatory signalling in individuals with defective downregulation of acute inflammation. The association between increased mortality and persistent elevation of proinflammatory chemokines in the serum of patients with acute coronary syndromes might reflect the adverse consequences of prolonged inflammation on the remodelling myocardium. 71 However, certain subpopulations of patient, such as those with diabetes, have post infarction heart failure in the absence of clinically relevant dilatation. 118 In patients with diabetes, postinfarction heart failure is often linked with diastolic dysfunction, 119 and might reflect excessive activation of the profibrotic TGF-β/Smad axis. 120 Different therapeutic strategies are, therefore, needed for these pathophysiologically distinct patient subpopulations.
The development of strategies to identify subgroups of patients with distinct pathophysiological alterations represents an important step towards implementation of effective therapy targeting the inflammatory and fibrotic response in myocardial infarction. Biomarker-based strategies are needed to identify individuals with overactive inflammatory responses and patients with excessive fibrosis (Figure 4 ). Serum levels of inflammatory cytokines and chemokines might provide useful information on the underlying pathophysiology. However, such markers are influenced by a wide range of clinical and pathological conditions, such as the extent of atherosclerotic disease, diabetes, obesity, and metabolic dysfunction, and might not reflect alterations in the myocardial inflammatory and reparative process. Molecular imaging modalities can reveal structural, cellular, and molecular alterations in the infarcted heart, and might be particularly promising for identification of patients with overactive inflammatory responses. Patients with such a response might benefit from targeted antiinflammator y approaches, such as pharmacological interventions to inhibit MCP-1 or IL-1. The crucial role of the IL-1 system in postinfarction inflammation, 43 the availability of effective IL-1 inhibitors and neutralizing antibodies, 121 the safety of IL-1 antagonists in patients Figure 4 | Biomarker-based approaches to target the inflammatory response in patients with acute myocardial infarction. Patients surviving a myocardial infarction exhibit pathophysiologically heterogeneous responses, which are partly independent of the size of the infarct. Distinct pathophysiological responses might be related to differences in genetic background and to the presence of conditions, such as diabetes mellitus or hypertension, which affect inflammatory and fibrogenic pathways. After myocardial infarction, some patients develop progressive dilatation and systolic dysfunction, whereas others develop diastolic dysfunction. Dilatation might reflect excessive inflammatory activity causing matrix degradation. Conversely, diastolic dysfunction might indicate overactive profibrotic signalling. We propose the measurement of inflammatory biomarkers, such as serum cytokine and chemokine levels, and of profibrotic markers, including indicators of matrix synthesis and remodelling, to stratify patients into subpopulations based on the predominant pathophysiology. Patients with overactive inflammation might benefit from targeted inhibition of inflammatory signals (anti-IL-1 or anti-MCP-1 strategies), whereas patients with profibrotic responses might benefit from inhibition of the TGF-β/smad cascade. Abbreviation: MCP-1, monocyte chemoattractant protein 1 (also known as CC motif chemokine 2).
with rheumatic disease, and the promising results of treatment with the IL-1 receptor antagonist anakinra in patients with ST-segment elevation myocardial infarction, 122, 123 explain the recent focus of the cardiovascular community on IL-1-related targets. Conversely, biomarkers that reflect excessive extracellular matrix protein synthesis 124 or overactive TGF-β responses might be useful in identification of individuals with predominant fibrotic remodelling. These patients might benefit from inhibition of Smad3. With careful exclusion of patients vulnerable to aneurysmal dilation, the potential adverse consequences of Smad inhibition in vascular remodelling might be avoided. 125, 126 Development of personalized, biomarker-based approaches are, therefore, needed to effectively target inflammatory signalling in patients with myocardial infarction. 127 
Conclusions
Inflammatory pathways are critically involved in the repair and adverse remodelling of the infarcted heart. Therapeutic approaches targeting specific components of the inflammatory response are promising for patients with myocardial infarction. However, the complexity of the pathophysiological process in humans is a major challenge for clinical translation. Biomarker and i magingbased strategies identifying patient subpopulations with overactive proinflammatory or fibrogenic signalling might contribute to rational implementation of therapies to prevent postinfarction heart failure.
Review criteria
The PubMed database was searched for Englishlanguage articles published between January 1970 and January 2014 using the following keywords: "myocardial infarction", "cardiac remodeling", "inflammation", "fibrosis", "cytokine", "chemokine", "leukocyte", "neutrophil", "monocytes", "myofibroblast", "interleukin-1", "interleukin-6", "TGF-β", "infarct healing" and "extracellular matrix". Abstracts were reviewed and manuscripts focusing on the role of inflammatory and reparative cascades in cardiac injury, repair, and remodeling were analyzed in detail. The reference sections of these articles were also consulted to identify additional papers of potential interest.
